Discounted Cash Flow
XTL Biopharmaceuticals Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-2.6m | — | — | — |
| 2017 | — | $-1.2m (51.3%) | $-344.0k | — | $-0.00 |
| 2018 | — | $-793.0k (36.4%) | — | — | $0.01 (400.0%) |
| 2019 | — | $-842.0k (-6.2%) | — | — | $-0.00 (-150.0%) |
| 2020 | — | $-948.0k (-12.6%) | $-68.0k | — | $-0.00 (33.3%) |
| 2021 | — | $-1.0m (-8.8%) | $-1.5m (-2082.4%) | — | $0.00 (150.0%) |
| 2022 | — | $-880.0k (14.6%) | $447.0k (130.1%) | — | $-0.00 (-300.0%) |
| 2023 | $41.0k | $-1.8m (-102.5%) | $1.1m (140.5%) | -4346.3% | $-0.00 (-50.0%) |
| 2024 | $451.0k (1000.0%) | $-1.2m (35.1%) | $-645.0k (-160.0%) | -256.5% (94.1%) | $-0.00 (33.3%) |
| 2025 | — | $-7.0m (-502.3%) | $5.9m (1021.6%) | — | $-0.01 (-300.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.